



SDI Review Form 1.6

PART 1:

Journal Name:	British Journal of Medicine and Medical Research
Manuscript Number:	MS: 2012 BJMMR 2989
Title of the Manuscript:	Severe Symptomatic Hypocalcemia after Denosumab Administration in an End-Stage Renal Disease Patient on Peritoneal Dialysis with Secondary Hyperparathyroidism – A Different Mechanism for Hungry Bone Syndrome.

General guideline for Peer Review process is available in this link:

<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>

- This form has total 9 parts. Kindly note that you should use all the parts of this review form.



SDI Review Form 1.6

PART 2: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<u>Compulsory</u> REVISION comments	<ol style="list-style-type: none"> 1. The selection of the title "bone hungry" is not appropriate. 2. In figure1 show when denosumab was initiated and when alendronate was discontinued. 	
<u>Minor</u> REVISION comments	<ol style="list-style-type: none"> 1. The author's should attempt to emphasize the side effects of a combined antiresorptive agents on calcium homeostasis in patients with end stage renal disease. 2. In the discussion the authors should allude to the long half-life of alendronate in bone and instruct the practioner not to use bisphosphonates in patients with cramoibdfj renal function. 3. The authors should note that it is possible that if denosumab was started after a reasonable period of time after alendronate treatment the ___ treatment did not occur. 3. Indicate whether Ca is adjusted for albumin in Table1. 4. The pathophysiological mechanisms included calcium mobilization from bone associated with 	



SDI Review Form 1.6

	<p>the residual antiresorptive effect of alendronate and simultaneous effect of denosumab on bone. These combined effects compiled with the compensatory rise of intestinal calcium absorption stimulating secondary hyperparathyroidism and enhancing bone turnover.</p>	
<p><u>Optional/General</u> comments</p>		

Reviewer Details:

<p>Name:</p>	<p>Khashayar Sakhaee, MD</p>
<p>Department, University & Country</p>	<p>Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, UT Southwestern Medical Center, USA</p>